GlaxoSmithKline begins £2bn share buyback programme
It forecasts that the repurchases will boost core earnings by 6% to 8% over the coming year
GlaxoSMithKline
-
-
Four views: Future prospects for the weight-loss sector
Portfolio Adviser asks this month’s panel for their views on the future prospects for a healthcare sector that seems to be booming
-
Five top-performing UK equity funds quietly achieving in an unloved sector
Using FE data, Portfolio Adviser shines a spotlight on the UK equity funds delivering the strongest, most reliable returns over the long term